Home

The document is the work of the Multi-Specialty and Multi-Society Coalition for Patient Safety With Paclitaxel Technologies, which includes three leading vascular surgical membership bodies: the Society for Vascular Surgery (SVS), the Vascular and Endovascular Surgery Society (VESS), and the Society for Clinical Vascular Surgery (SCVS).

The US Food and Drug Administration (FDA) tasked the coalition with putting together bullet points that reflect the current evidence around the hot topic of paclitaxel devices.

The American College of Cardiology, American College of Radiology, American Heart Association, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine, and the Society of Interventional Radiology make up the remainder of the membership bodies on the coalition.

“The coalition bullet points reflect the current evidence surrounding this complex topic and is designed to help institutions and members to use when discussing increased rate of long-term mortality in patients treated with paclitaxel-coated balloons and paclitaxel-eluting stents,” the coalition stated.

“The statements are intended to summarise the current state of the evidence and to serve as starting points for discussion. We recognise this is a complex issue and the talking points and are not intended to take the place of thoughtful, individualised discussions with patients.

“The ability to effectively communicate risk and benefit of revascularisation is key part of procedure selection. Please consider the following statement in your discussions and informed consent process.” The document follows in full.

Peripheral vascular intervention talking points for informing patients about the paclitaxel safety signal

A recent meta-analysis of randomised trials suggests an increased mortality rate after two years in peripheral artery disease (PAD) patients treated with paclitaxel-coated balloons and paclitaxel-eluting stents for femoropopliteal disease compared to patients treated with uncoated balloons or bare metal stents. The FDA recommends that physicians discuss the risks and benefits of all available treatment options with their PAD patients.

To this end, a Multi-Specialty Paclitaxel Coalition (American College of Cardiology, American College of Radiology, American Heart Association, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine, Society of Interventional Radiology, Society for Vascular Surgery, Vascular and Endovascular Surgery Society, and the Society for Clinical Vascular Surgery), representing the majority of specialists who evaluate and treat patients with PAD, developed the following talking points, which have been reviewed by the FDA, that physicians/providers may consider when discussing PAD treatment options with their patients:

Some balloons and stents used to treat symptoms resulting from blocked blood vessels in leg(s) are coated with the drug paclitaxel.
Research studies show that paclitaxel-coated balloons and stents improve the chance that the treated blood vessel in your leg will remain open after your treatment and lower the likelihood that you will need a repeat procedure to re-open the vessel.
However, an analysis in 2019 that combined the results from multiple studies indicated that the use of paclitaxel-coated balloons and stents may increase your chance of dying starting about two years after treatment. Although this analysis has limitations and further research is still ongoing, the available information as of April 2020 suggests that paclitaxel-coated device use may increase your chance of dying over the next 2–5 years compared to treatment with uncoated balloons or bare metal stents.
There may be other options for the treatment of your symptoms, including medications, exercise, balloons, stents or other devices that do not contain paclitaxel, and surgery. You and your doctor should discuss the possible risks and benefits of all treatments to identify those options that are best for you.

The Multi-Specialty Paclitaxel Coalition is actively working with the FDA, medical device manufacturers, and clinical investigators to advance our understanding of the long-term safety and effectiveness of paclitaxel-coated devices.

Source VascularNews

Duc Tin Clinic

Chia sẽ qua facebook bài: Vascular surgeons encouraged to consult talking points document on paclitaxel devices

Chia sẽ qua google bài: Vascular surgeons encouraged to consult talking points document on paclitaxel devices

Chia sẽ qua twitter bài: Vascular surgeons encouraged to consult talking points document on paclitaxel devices

Chia sẽ qua MySpace bài: Vascular surgeons encouraged to consult talking points document on paclitaxel devices

Chia sẽ qua LinkedIn bài: Vascular surgeons encouraged to consult talking points document on paclitaxel devices

Chia sẽ qua stumbleupon bài: Vascular surgeons encouraged to consult talking points document on paclitaxel devices

Chia sẽ qua icio bài: Vascular surgeons encouraged to consult talking points document on paclitaxel devices

Chia sẽ qua digg bài: Vascular surgeons encouraged to consult talking points document on paclitaxel devices

Chia sẽ qua yahoo bài: Vascular surgeons encouraged to consult talking points document on paclitaxel devices

Tin tức liên quan

Enrolment reaches midway point in trial of Early Bird bleed monitoring system

Eight-fold increased risk of heart attack seen in patients with subclinical obstructive coronary atherosclerosis

ACC 2023: REVIVED-BCIS-2 results challenge “long-held beliefs” on myocardial viability testing prior to PCI

Blood pressure successfully cut in RADIANCE II ultrasound renal denervation trial

New data examine mortality rates and cardiac damage in early-stage aortic stenosis patients

SUPPORT CONSULTANT

Make an Appointment

I am Nguyen Thanh Sang, born in 1990. Since the examination and treatment at the clinic Duc Tin, I am very grateful to the Doctor for explaining and sharing about my illness. During the treatment time in the clinic I was very caring staff of the clinic. Now my illness has improved in a good way. Expect more and more clinic to be able to save many patients.

I sincerely thank you !. Tel: 0938303275

Huynh Thi Muoi, born in 1940, was examined and treated at Duc Tin Clinic. I am very pleased about how to serve and care patients of the clinic. The doctor is committed to explaining and sharing with the patient.

Huynh Thi Muoi sincerely thank you! Phone number: 0972868746

As I said Duc Tin surgical clinin is where my family trust, hope to visit. Physicians caring, thoughtful, gentle to the patient. Nurses and staff clinic polite, cheerful and thoughtful. This clinic clean, sterile, so I would love to. Tel: +84949914060.

The doctor is very caring, attentive and very gentle nurse, courteous, affable with me. The clinic is clean, comfortable, polite. I enjoyed this faith. Every visit I was very relieved disease. Tel: 0839820792.

I was patient, had to clinics of Dr. Le Duc Tin. I see very conscientious doctor patient care, answer any questions and very dedicated staff from the receptionist to the children tested, nursing. Clinics very clean and spacious. I'm very satisfied. Tel: +841227880829.